ArticleClinical rheumatology2026
Global burden and inequalities of rheumatoid arthritis in adults aged 15-49 years from 1990 to 2021 and projections to 2050: a cross-sectional analysis from Global Burden of Disease Study 2021.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveGiven that rheumatoid arthritis (RA) in working-age adults poses rising global health and economic challenges, we assessed the global, regional, and national burden of RA among adults aged 15-49 years from 1990 to 2021 and projected trends to 2050.
methodsWe analyzed Global Burden of Disease 2021 data from 204 countries. Age-standardized rates of RA incidence, prevalence, and disability-adjusted life-years (DALYs) were calculated. Decomposition analysis quantified contributions of population growth, aging, and epidemiological changes. Frontier analysis identified best-performing countries. Bayesian age-period-cohort models projected trends to 2050.
resultsGlobal RA prevalence among 15-49-year-olds increased 87.7% from 3.23 million cases (95% UI: 2.59-3.95 million) in 1990 to 6.07 million (4.90-7.36 million) in 2021. Age-standardized prevalence rose 29% (119.20 to 153.73 per 100,000). Women experienced 2.8-fold higher rates than men (228.3 vs 81.0 per 100,000). High Socio-demographic Index (SDI) countries showed triple the prevalence of low SDI countries (209 vs 65 per 100,000). Latin America recorded the highest regional rates (Andean: 420.7 per 100,000). Population growth accounted for 68% of case increases, with epidemiological changes contributing 24%. Smoking-attributable burden declined from 8.8% to 6.5% of DALYs. Projected cases will reach 7.48 million by 2050 (26.8% increase).
conclusionRA burden among working-age adults has nearly doubled since 1990, with persistent inequities by sex and development level. The projected increase to 7.48 million cases by 2050 demands urgent global action, including integrating RA into chronic disease programs and expanding early diagnosis access. Key Points • RA cases in working-age adults nearly doubled from 3.23 to 6.07 million (1990-2021) • Women experience 2.8-fold higher RA rates and comprise 73% of all cases • High SDI countries show triple the prevalence of low SDI countries • Projected a 26.8% increase to 7.48 million cases by 2050 without intervention.
Indexed as
Identifiers
42098526What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.